Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2019

Open Access 01-12-2019 | Solid Tumor | Study protocol

Cognitively-Based Compassion Training versus cancer health education to improve health-related quality of life in survivors of solid tumor cancers and their informal caregivers: study protocol for a randomized controlled pilot trial

Authors: Thaddeus W. W. Pace, Sally E. Dodds, Alla Sikorskii, Terry A. Badger, Chris Segrin, Lobsang Tenzin Negi, Timothy Harrison, Tracy E. Crane

Published in: Trials | Issue 1/2019

Login to get access

Abstract

Background

Cancer survivors and their informal caregivers (family members, close friends) often experience significant impairments in health-related quality of life (HRQOL), including disruptions in psychological, physical, social, and spiritual well-being both during and after primary cancer treatment. The purpose of this in-progress pilot trial is to determine acceptability and preliminary efficacy (as reflected by effect sizes) of CBCT® (Cognitively-Based Compassion Training) compared with a cancer health education (CHE) attention control to improve the primary outcome of depressive symptoms and secondary outcomes of other HRQOL domains (e.g., anxiety, fatigue), biomarkers of inflammation and diurnal cortisol rhythm, and healthcare utilization-related outcomes in both cancer survivors and informal caregivers.

Methods

Forty dyads consisting of solid tumor survivors who have completed primary treatments (chemotherapy, radiation, surgery) and their informal caregivers, with at least one dyad member with ≥ mild depressive symptoms or anxiety, will be recruited from Tucson, Arizona, USA. Survivor-caregiver dyads will be randomized together to complete either CBCT or CHE. CBCT is a manualized, 8-week, group meditation-based intervention that starts with attention and mindfulness and builds to contemplative practices aimed at cultivating compassion to the self and others. The goal of CBCT is to challenge unexamined assumptions about feelings and behaviors, with a focus on generating spontaneous self-compassion and increased empathic responsiveness and compassion for others. CHE is an 8-week, manualized group intervention that provides cancer-specific education on various topics (e.g., cancer advocacy, survivorship wellness). Patient-reported HRQOL outcomes will be assessed before, immediately after (week 9), and 1 month after CBCT or CHE (week 13). At the same time points, stress-related biomarkers of inflammation (e.g., plasma interleukin-6) and saliva cortisol relevant for survivor and informal caregiver wellness and healthcare utilization will be measured.

Discussion

If CBCT shows acceptability, a larger trial will be warranted and appropriately powered to formally test the efficacy of this dyadic intervention. Interventions such as CBCT directed toward both survivors and caregivers may eventually fill a gap in supportive oncology care programs to improve HRQOL and healthcare utilization in both dyad members.

Trial registration

Clinicaltrials.gov, NCT03459781. Prospectively registered on 9 March 2018.
Appendix
Available only for authorised users
Literature
1.
2.
Tung HY, Chao TB, Lin YH, Wu SF, Lee HY, Ching CY, Hung KW, Lin TJ. Depression, fatigue, and QoL in colorectal cancer patients during and after treatment. West J Nurs Res. 2016;38(7):893–908.PubMedCrossRef
3.
Watts S, Leydon G, Birch B, Prescott P, Lai L, Eardley S, Lewith G. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open. 2014;4(3):e003901.PubMedPubMedCentralCrossRef
4.
Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, Gralow J. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry. 2008;30(2):112–26.PubMedCrossRef
5.
Krebber AM, Buffart LM, Kleijn G, Riepma IC, de Bree R, Leemans CR, Becker A, Brug J, van Straten A, Cuijpers P, Verdonck-de Leeuw IM. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. 2014;23(2):121–30.PubMedCrossRef
6.
Schneider EC, Malin JL, Kahn KL, Ko CY, Adams J, Epstein AM. Surviving colorectal cancer: patient-reported symptoms 4 years after diagnosis. Cancer. 2007;110(9):2075–82.PubMedCrossRef
7.
Colloca G, Venturino A, Governato I, Checcaglini F. Incidence and correlates of fatigue in metastatic castration-resistant prostate cancer: a systematic review. Clin Genitourin Cancer. 2016;14(1):5–11.PubMedCrossRef
8.
Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12(Suppl 1):4–10.PubMedCrossRef
9.
Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr. 2004;32:40–50.CrossRef
10.
Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK, Vogelzang NJ. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist. 2000;5(5):353–60.PubMedCrossRef
11.
Saboonchi F, Petersson LM, Wennman-Larsen A, Alexanderson K, Vaez M. Trajectories of anxiety among women with breast cancer: a proxy for adjustment from acute to transitional survivorship. J Psychosoc Oncol. 2015;33(6):603–19.PubMedCrossRef
12.
Maass SW, Roorda C, Berendsen AJ, Verhaak PF, de Bock G. The prevalence of long-term symptoms of depression and anxiety after breast cancer treatment: a systematic review. Maturitas. 2015;82(1):100–8.PubMedCrossRef
13.
Eisenberg SA, Kurita K, Taylor-Ford M, Agus DB, Gross ME, Meyerowitz BE. Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors. Psychooncology. 2015;24(2):228–35.PubMedCrossRef
14.
Lowery AE, Krebs P, Coups EJ, Feinstein MB, Burkhalter JE, Park BJ, Ostroff JS. Impact of symptom burden in post-surgical non-small cell lung cancer survivors. Support Care Cancer. 2014;22(1):173–80.PubMedCrossRef
15.
Custers JA, Gielissen MF, Janssen SH, de Wilt JH, Prins JB. Fear of cancer recurrence in colorectal cancer survivors. Support Care Cancer. 2016;24(2):555–62.PubMedCrossRef
16.
Braamse AM, van Turenhout ST, Terhaar Sive Droste JS, de Groot GH, van der Hulst RW, Klemt-Kropp M, Kuiken SD, Loffeld RJ, Uiterwaal MT, Mulder CJ, Dekker J. Factors associated with anxiety and depressive symptoms in colorectal cancer survivors. Eur J Gastroenterol Hepatol. 2016;28(7):831–5.PubMedCrossRef
17.
Lambert SD, Girgis A, Lecathelinais C, Stacey F. Walking a mile in their shoes: anxiety and depression among partners and caregivers of cancer survivors at 6 and 12 months post-diagnosis. Support Care Cancer. 2013;21(1):75–85.PubMedCrossRef
18.
Cubukcu M. Evaluation of quality of life in caregivers who are providing home care to cancer patients. Support Care Cancer. 2018;26(5):1457–63.PubMed
19.
Kent EE, Rowland JH, Northouse L, Litzelman K, Chou WY, Shelburne N, Timura C, O’Mara A, Huss K. Caring for caregivers and patients: research and clinical priorities for informal cancer caregiving. Cancer. 2016;122(13):1987–95.PubMedCrossRef
20.
Northouse L, McCorkle R. Spouse caregivers of cancer patients. In: Holland JCBW, Butow PN, Jacobsen PB, Loscalzo MJ, McCorkle R, editors. Psycho-oncology. 3rd ed. New York: Oxford University Press; 2015. p. 567–78.
21.
Litzelman K, Kent EE, Mollica M, Rowland JH. How does caregiver well-being relate to perceived quality of care in patients with cancer? Exploring associations and pathways. J Clin Oncol. 2016;34(29):3554–3561.PubMedPubMedCentralCrossRef
22.
Sherwood PR, Price TJ, Weimer J, Ren D, Donovan HS, Given CW, Given BA, Schulz R, Prince J, Bender C, Boele FW, Marsland AL. Neuro-oncology family caregivers are at risk for systemic inflammation. J Neuro-Oncol. 2016;128(1):109–18.CrossRef
23.
Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci U S A. 2003;100(15):9090–5.PubMedPubMedCentralCrossRef
24.
25.
Segrin C, Badger TA. Psychological and physical distress are interdependent in breast cancer survivors and their partners. Psychol Health Med. 2014;19(6):716–23.PubMedCrossRef
26.
Segrin C, Badger TA, Harrington J. Interdependent psychological quality of life in dyads adjusting to prostate cancer. Health Psychol. 2012;31(1):70–9.PubMedCrossRef
27.
Hatfield E, Cacioppo JT, Rapson RL. Emotional contagion. Cambridge: Cambridge University Press; 1994.
28.
Ozawa-de Silva B, Negi LT. Cognitively-Based Compassion Training (CBCT): protocol and key concepts. In: Singer T, Bolz M, editors. Compassion: bridging practice and science. Munich: Max Planck Society; 2013. p. 416–38.
29.
Ozawa-de Silva B, Dodson-Lavelle B. Education of heart and mind: practical and theoretical issues in teaching Cognitively-Based Compassion Training to children. Practial Matters. 2011;4:1–28.
30.
Dodds SE, Pace TWW, Bell ML, Fiero M, Negi LT, Raison CL, Weihs KL. Feasibility of Cognitively-Based Compassion Training (CBCT) for breast cancer survivors: a randomized, wait list controlled pilot study. Support Care Cancer. 2015;23(12):3599–608.PubMedCrossRef
31.
Mascaro JS, Rilling JK, Tenzin Negi L, Raison CL. Compassion meditation enhances empathic accuracy and related neural activity. Soc Cogn Affect Neurosci. 2013;8(1):48–55.PubMedCrossRef
32.
Pace TWW, Negi LT, Dodson-Lavelle B, Ozawa-de Silva B, Reddy SD, Cole SP, Danese A, Craighead LW, Raison CL. Engagement with Cognitively-Based Compassion Training is associated with reduced salivary C-reactive protein from before to after training in foster care program adolescents. Psychoneuroendocrinology. 2013;38(2):294–9.PubMedCrossRef
33.
Reddy SD, Negi LT, Dodson-Lavelle B, Ozawa-de Silva B, Pace TWW, Cole SP, Raison CL, Craighead LW. Cognitively-based Compassion Training: a promising prevention strategy for at-risk adolescents. J Child Fam Stud. 2012;22(2):219–30.CrossRef
34.
Desbordes G, Negi LT, Pace TWW, Wallace BA, Raison CL, Schwartz EL. Effects of mindful-attention and compassion meditation training on amygdala response to emotional stimuli in an ordinary, non-meditative state. Front Hum Neurosci. 2012;6:292.PubMedPubMedCentralCrossRef
35.
Pace TWW, Negi LT, Sivilli TI, Issa MJ, Cole SP, Adame DD, Raison CL. Innate immune, neuroendocrine and behavioral responses to psychosocial stress do not predict subsequent compassion meditation practice time. Psychoneuroendocrinology. 2010;35(2):310–5.PubMedCrossRef
36.
Pace TWW, Negi LT, Adame DD, Cole SP, Sivilli TI, Brown TD, Issa MJ, Raison CL. Effect of compassion meditation on neuroendocrine, innate immune and behavioral responses to psychosocial stress. Psychoneuroendocrinology. 2009;34(1):87–98.PubMedCrossRef
37.
Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–56.PubMedPubMedCentralCrossRef
38.
39.
Cheruvu VK, Oancea SC. Current depression as a potential barrier to health care utilization in adult cancer survivors. Cancer Epidemiol. 2016;44:132–7.PubMedCrossRef
40.
Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, Amtmann D, Bode R, Buysse D, Choi S, Cook K, Devellis R, DeWalt D, Fries JF, Gershon R, Hahn EA, Lai JS, Pilkonis P, Revicki D, Rose M, Weinfurt K, Hays R. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol. 2010;63(11):1179–94.PubMedPubMedCentralCrossRef
41.
Pulos S, Elison J, Lennon R. The hierarchical structure of the Interpersonal Reactivity Index. Soc Behav Pers. 2004;32:355–9.CrossRef
42.
Davis MH. Measuring individual differences in empahty: evidence for a multi-dimensional approach. J Pers Soc Psychol. 1983;44:113–26.CrossRef
43.
Davis MH. Empathy: a social psychological approach. Boulder: Westview Press; 1994.
44.
Lee RM, Draper M, Lee S. Social connectedness, dysfunctional interpersonal behaviors, and psychological distress: testing a mediator model. J Couns Psychol. 2001;48(3):310–8.CrossRef
45.
46.
Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988;54(6):1063–70.CrossRefPubMed
47.
Hendrick SS. A generic measure of relationship satisfaction. J Marriage Fam. 1988;50:93–8.CrossRef
48.
Neff KD. Development and validation of a scale to measure self-compassion. Self Identity. 2003;2:223–50.CrossRef
49.
Breines JG, Thoma MV, Gianferante D, Hanlin L, Chen X, Rohleder N. Self-compassion as a predictor of interleukin-6 response to acute psychosocial stress. Brain Behav Immun. 2014;37:109–14.PubMedCrossRef
50.
Lorig KR, Sobel DS, Ritter PL, Laurent D, Hobbs M. Effect of a self-management program on patients with chronic disease. Eff Clin Pract. 2001;4(6):256–62.PubMed
51.
Kirchhoff AC, Lyles CR, Fluchel M, Wright J, Leisenring W. Limitations in health care access and utilization among long-term survivors of adolescent and young adult cancer. Cancer. 2012;118(23):5964–72.PubMedCrossRef
52.
Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004;39(4 Pt 1):1005–26.PubMedPubMedCentralCrossRef
53.
Hibbard JH, Mahoney ER, Stockard J, Tusler M. Development and testing of a short form of the patient activation measure. Health Serv Res. 2005;40(6 Pt 1):1918–30.PubMedPubMedCentralCrossRef
54.
Quinn AM, Williams AR, Sivilli TI, Raison CL, Pace TWW. The plasma interleukin-6 response to acute psychosocial stress in humans is detected by a magnetic multiplex assay: comparison to high-sensitivity ELISA. Stress. 2018;21(4):376–381.PubMedCrossRefPubMedCentral
55.
Torres MA, Pace TWW, Liu T, Felger JC, Mister D, Doho GH, Kohn JN, Barsevick AM, Long Q, Miller AH. Predictors of depression in breast cancer patients treated with radiation: role of prior chemotherapy and nuclear factor kappa B. Cancer. 2014;119(11):1951–9.CrossRef
56.
Pace TWW, Wingenfeld K, Schmidt I, Meinlschmidt G, Hellhammer DH, Heim CM. Increased peripheral NF-kappaB pathway activity in women with childhood abuse-related posttraumatic stress disorder. Brain Behav Immun. 2012;26(1):13–7.PubMedCrossRef
57.
Pace TWW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH, Heim CM. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry. 2006;163(9):1630–3.CrossRefPubMed
58.
Negi LT. Emory compassion meditation protocol: Cognitively-Based Compassion Training manual. Atlanta: Emory University; 2013.
59.
Ozawa-de Silva B, Dodson-Lavelle B, Raison CL, Negi LT. Compassion and ethics: scientific approaches to the cultivation of compassion as a foundation for ethical subjectivity and well-being. J Healthcare Sci Human. 2012;11(1):145–57.
60.
Badger TA, Segrin C, Figueredo AJ, Harrington J, Sheppard K, Passalacqua S, Pasvogel A, Bishop M. Psychosocial interventions to improve quality of life in prostate cancer survivors and their intimate or family partners. Qual Life Res. 2011;20(6):833–44.PubMedCrossRef
61.
Badger TA, Segrin C, Hepworth JT, Pasvogel A, Weihs K, Lopez AM. Telephone-delivered health education and interpersonal counseling improve quality of life for Latinas with breast cancer and their supportive partners. Psychooncology. 2013;22(5):1035–42.PubMedCrossRef
62.
Cella D, Eton DT, Fairclough DL, Bonomi P, Heyes AE, Silberman C, Wolf MK, Johnson DH. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) study 5592. J Clin Epidemiol. 2002;55(3):285–95.PubMedCrossRef
63.
Sloan JA, Cella D, Hays RD. Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol. 2005;58(12):1217–9.PubMedCrossRef
64.
Segrin C, Badger TA, Sikorskii A, Crane TE, Pace TWW. A dyadic analysis of stress processes in Latinas with breast cancer and their family caregivers. Psychooncology. 2018;27(3):838–46.PubMedCrossRef
65.
Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. 2008;26(6):971–82.PubMedCrossRef
66.
Collado-Hidalgo A, Bower JE, Ganz PA, Irwin MR, Cole SW. Cytokine gene polymorphisms and fatigue in breast cancer survivors: early findings. Brain Behav Immun. 2008;22(8):1197–200.PubMedPubMedCentralCrossRef
67.
Bower JE. Prevalence and causes of fatigue after cancer treatment: the next generation of research. J Clin Oncol. 2005;23(33):8280–2.PubMedCrossRef
68.
Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med. 2002;64(4):604–11.PubMedCrossRef
69.
Bower JE, Ganz PA, Tao ML, Hu W, Belin TR, Sepah S, Cole S, Aziz N. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin Cancer Res. 2009;15(17):5534–40.PubMedPubMedCentralCrossRef
70.
Wratten C, Kilmurray J, Nash S, Seldon M, Hamilton CS, O’Brien PC, Denham JW. Fatigue during breast radiotherapy and its relationship to biological factors. Int J Radiat Oncol Biol Phys. 2004;59(1):160–7.PubMedCrossRef
71.
Collado-Hidalgo A, Bower JE, Ganz PA, Cole SW, Irwin MR. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res. 2006;12(9):2759–66.PubMedCrossRef
72.
Musselman DL. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatr. 2001;158(8):1252–7.PubMedCrossRef
73.
Marsland AL, Walsh C, Lockwood K, John-Henderson NA. The effects of acute psychological stress on circulating and stimulated inflammatory markers: a systematic review and meta-analysis. Brain Behav Immun. 2017;64:208–19.PubMedPubMedCentralCrossRef
74.
Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171–86.CrossRefPubMed
75.
Miller GE, Murphy ML, Cashman R, Ma R, Ma J, Arevalo JM, Kobor MS, Cole SW. Greater inflammatory activity and blunted glucocorticoid signaling in monocytes of chronically stressed caregivers. Brain Behav Immun. 2014;41:191–9.PubMedPubMedCentralCrossRef
76.
Bower JE, Ganz PA, Irwin MR, Arevalo JM, Cole SW. Fatigue and gene expression in human leukocytes: increased NF-kappaB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain Behav Immun. 2011;25(1):147–50.PubMedCrossRef
77.
Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression. Soc Biol Psychiatry. 2003;54:269–82.CrossRef
78.
Spiegel D, Giese-Davis J, Taylor CB, Kraemer H. Stress sensitivity in metastatic breast cancer: analysis of hypothalamic-pituitary-adrenal axis function. Psychoneuroendocrinology. 2006;31(10):1231–44.PubMedPubMedCentralCrossRef
79.
Giese-Davis J, Spiegel D. Emotional expression and cancer progression. In: Davidson RJ, Scherer K, Hill Goldsmith H, eds. Series in affective science. Handbook of affective sciences. New York, NY: Oxford University Press; 2003:1053–1082.
80.
Giese-Davis J, Wilhelm FH, Conrad A, Abercrombie HC, Sephton S, Yutsis M, Neri E, Taylor CB, Kraemer HC, Spiegel D. Depression and stress reactivity in metastatic breast cancer. Psychosom Med. 2006;68(5):675–83.PubMedCrossRef
81.
Giese-Davis J, Collie, et al. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol. 2010;29(4):413–20.PubMedPubMedCentralCrossRef
82.
Bower JE, Ganz PA, Dickerson SS, Peterson L, Azia N, Fahey JL. Diurnal cortisol rhythm and fatigue in breast cancer survivors. PsychoNeuroendocrinology. 2005;30:92–100.PubMedCrossRef
83.
Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92(12):994–1000.PubMedCrossRef
84.
Chida Y, Hamer M, Wardle J, Steptoe A. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol. 2008;5(8):466–75.PubMedCrossRef
85.
Jarcho MR, Slavich GM, Tylova-Stein H, Wolkowitz OM, Burke HM. Dysregulated diurnal cortisol pattern is associated with glucocorticoid resistance in women with major depressive disorder. Biol Psychol. 2013;93(1):150–8.PubMedPubMedCentralCrossRef
86.
Spiegel D, Giese-Davis J, Taylor CB, Kraemer H. Stress sensitivity in metastatic breast cancer: analysis of the hypothalmic-pituitary-adrenal axis function. PsychoNeuroendocrinology. 2006;31:1231–44.PubMedPubMedCentralCrossRef
87.
Giese-Davis J, Sephton SE, Abercrombie HC, Duran RE, Spiegel D. Repression and high anxiety are associated with aberrant diurnal cortisol rhythms in women with metastatic breast cancer. Health Psychol. 2004;23(6):645–50.PubMedCrossRef
88.
Abercrombie HC, Giese-Davis J, Sephton S, Epel ES, Turner-Cobb JM, Spiegel D. Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology. 2004;29(8):1082–92.PubMedCrossRef
89.
Turner-Cobb JM, Sephton SE, Koopman C, Blake-Mortimer J, Spiegel D. Social support and salivary cortisol in women with metastatic breast cancer. Psychosom Med. 2000;62(3):337–45.PubMedCrossRef
Metadata
Title
Cognitively-Based Compassion Training versus cancer health education to improve health-related quality of life in survivors of solid tumor cancers and their informal caregivers: study protocol for a randomized controlled pilot trial
Authors
Thaddeus W. W. Pace
Sally E. Dodds
Alla Sikorskii
Terry A. Badger
Chris Segrin
Lobsang Tenzin Negi
Timothy Harrison
Tracy E. Crane
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Solid Tumor
Published in
Trials / Issue 1/2019
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-019-3320-9

Other articles of this Issue 1/2019

Trials 1/2019 Go to the issue

Correction

Correction to: Efficiency and safety of renal denervation via cryoablation (Cryo-RDN) in Chinese patients with uncontrolled hypertension: study protocol for a randomized controlled trial

Study protocol

MOTANA: study protocol to investigate motor cerebral activity during a propofol sedation

Study protocol

Songling Xuemaikang capsules for patients with low-to-medium risk hypertension: study protocol for a randomized controlled trial

Commentary

Building internal capacity in pragmatic trials: a workshop for program scientists at the US National Cancer Institute

Study protocol

Antibiotic Review Kit for Hospitals (ARK-Hospital): study protocol for a stepped-wedge cluster-randomised controlled trial

Research

Reporting quality and adherence of randomized controlled trials about statins and/or fibrates for diabetic retinopathy to the CONSORT checklist